Triple negative phenotype and N-ratio are important for prognosis in patients with stage IIIB non-inflammatory breast carcinoma

2009 ◽  
Vol 100 (8) ◽  
pp. 681-687 ◽  
Author(s):  
Hakan Mersin ◽  
Emin Yildirim ◽  
Ugur Berberoglu ◽  
Kaptan Gulben
Keyword(s):  
Breast Carcinoma ◽  
Triple Negative ◽  
Stage Iiib ◽  
Inflammatory Breast Carcinoma ◽  
Triple Negative Phenotype ◽  
Negative Phenotype

scholarly journals Immunohistochemical profile and its association with clinicopathological parameters in carcinoma breast: a prospective study in central India

2019 ◽  
Vol 7 (5) ◽  
pp. 1796
Author(s):  
Vaishali Walke ◽  
Gajanan Gunjkar
Keyword(s):  
Lymph Node ◽  
Breast Carcinoma ◽  
Triple Negative ◽  
Tumour Size ◽  
Clinicopathological Parameters ◽  
Low Grade ◽  
Duct Carcinoma ◽  
Carcinoma Breast ◽  
Triple Negative Phenotype ◽  
Negative Phenotype

Background: Carcinoma breast is one of the most common malignancies of women in India. The current study was conducted with the objective of assessing estrogen receptor (ER), progesterone receptor (PR), Her-2/neu (human epidermal growth factor receptor-2) expression and Ki67 index of breast carcinomas and its correlation with histological grade, tumour size and lymph node metastasis.Methods: Forty-seven lumpectomy or modified mastectomy specimens diagnosed as Infiltrating duct carcinoma (IDC): NOS, were selected for panel of imuno histochemistry (IHC) markers on tissue microarray blocks prepared from each case.Results: Maximum of our patients belonged to premenopausal 24/47 (51%) and 20% to younger age group (<30 year). Tumour size of 2-5 cm was observed in maximum females 29 (61%); while 13(27%) had size >5.0cm. The majority of cases diagnosed as grade I (40%) and lymph node involvement was seen in 31/47 (65%). Molecular classification revealed 10 (21%) luminal A, 4 (8%) luminal B, 9 (19%) Her2/neu positive, while triple negative phenotype comprised of maximum 24 (51%) patients. Most of the Luminal group tumours were low grade (14/15); while majority of Her2/neu positive 7/9(77%) and triple negative tumours 19/24 (80%) belonged to higher grades.Conclusions: Breast carcinoma among our patient is characterized by a large percentage of triple negative phenotype that is less susceptible to hormonal therapy. The empirical treatment with tamoxifen should therefore be reconsidered as it would be less effective. Assessment of prognostic markers in breast carcinoma is strongly advocated in order to provide the best therapeutic options.

scholarly journals Antiangiogenic therapy for breast cancer with triple negative phenotype

2021 ◽  
Vol 23 (1) ◽  
pp. 88-92
Author(s):  
Inna P. Ganshina ◽  
Kristina A. Ivanova ◽  
Olga O. Gordeeva ◽  
Aleksandr V. Arkhipov ◽  
Liudmila G. Zhukova
Keyword(s):  
Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Malignant Tumors ◽  
Antiangiogenic Therapy ◽  
Treatment Strategies ◽  
Her 2 ◽  
Triple Negative Phenotype ◽  
The Impact ◽  
Negative Phenotype

Triple-negative breast cancer is 1024% of all cases of breast cancer and is characterized by the absence of estrogen, progesterone, and HER-2 receptors in the tumor. The therapy of this illness is a difficult clinical case. In contrast to hormone-positive and HER-2-positive phenotypes, in which we successfully use targeted drugs (antiestrogens and anti-HER-2 drugs), for triple-negative breast cancer we have not had such targets for a long time. Thus, despite the impressive results of immunotherapy of triple-negative breast cancer, there remains a fairly large group of patients with negative PD-L1 status, for whom it is necessary to develop other treatment strategies. One of the approaches in the treatment of malignant tumors includes not the impact on tumor cells, but the process of angiogenesis. Antiangiogenic drugs have positively proven themselves in the treatment of a large number of malignant tumors but are underestimated for breast cancer (including triple-negative phenotype). The use of bevacizumab in combinations with cytostatic drugs in breast cancer therapy (including triple-negative breast cancer) has been studied in a large number of clinical trials but was undeservedly forgotten in some countries due to the revoked FDA registration. This review presents the role of bevacizumab in the treatment of patients with triple-negative breast cancer and suggests the conditions when the administration of this drug is justified and leads to better results.

Carcinoma arising in microglandular adenosis of the breast: triple negative phenotype with variable morphology

Pathology ◽  
2014 ◽  
Vol 46 ◽  
pp. S53-S54
Author(s):  
Zhong Fangfang ◽  
Bi Rui ◽  
Yu Baohua ◽  
Cheng Yufan ◽  
Xu Xiaoli ◽  
...  
Keyword(s):  
Triple Negative ◽  
Variable Morphology ◽  
Triple Negative Phenotype ◽  
Microglandular Adenosis ◽  
Negative Phenotype

scholarly journals Breast Cancer During Pregnancy: A Marked Propensity to Triple-Negative Phenotype

2020 ◽  
Vol 10 ◽  
Author(s):  
Soumaya Allouch ◽  
Ishita Gupta ◽  
Shaza Malik ◽  
Halema F. Al Farsi ◽  
Semir Vranic ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Triple Negative ◽  
Cancer Therapeutics ◽  
Combination Therapies ◽  
Specific Group ◽  
Fatal Disease ◽  
Cervical Cancers ◽  
Deadly Disease ◽  
Triple Negative Phenotype ◽  
Negative Phenotype

Breast and cervical cancers comprise 50% of all cancers during pregnancy. In particular, gestational breast cancer is considered one of the most aggressive types of cancers, which is a rare but fatal disease. However, the incidence of this type of cancer is increasing over the years and its prevalence is expected to rise further as more women delay childbearing. Breast cancer occurring after pregnancy is generally triple negative with specific characterizations of a poorer prognosis and outcome. On the other hand, it has been pointed out that this cancer is associated with a specific group of genes which can be used as precise targets to manage this deadly disease. Indeed, combination therapies consisting of gene-based agents with other cancer therapeutics is presently under consideration. We herein review recent progress in understanding the development of breast cancer during pregnancy and their unique subtype of triple negative which is the hallmark of this type of breast cancer.

Sign in / Sign up

Export Citation Format

Share Document